Clinical Study Of Qinggan Erxian Decoction In The Treatment Of Type 1 Autoimmune Hepatitis With Deficiency Of Liver And Kidney Yin

Research purpose:To observe the improvement of liver function index,immunological index,clinical symptom and physical sign of Professor Zhong Sen's experience of QingGanerxian decoction in patients with liver and kidney yin deficiency syndrome of type I autoimmune hepatitis.To evaluate the efficacy of Qinggan Erxian decoction in treating type I autoimmune hepatitis with deficiency of liver and kidney yin.Objects and methods:From October 2013 to January 2018,the patients who were admitted to the Department of infection in Sichuan Provincial Hospital of traditional Chinese Medicine,according to the diagnostic criteria of autoimmune hepatitis and classified as type ?,were classified as type ? and according to the inclusion criteria strictly according to the inclusion criteria of TCM syndrome differentiation of liver and kidney yin deficiency.According to the random digital table,the patients were divided into two groups: the experimental group(n = 35),the control group(n = 35)and the control group(n = 70).The experimental group was treated with Professor Zhong Sen experience Qing Ganerxian decoction,the control group was treated with compound glycyrrhizin tablets(Meineng),both groups were taken continuously for 3months.The curative effect index includes liver function index,immunology index,TCM syndrome accumulation.Minutes.Each patient was examined for liver function before and after each course of treatment,immunoglobulin G was examined before and after the whole course of treatment,TCM syndromes score was calculated,and data were recorded.All the data in the study were analyzed by SPSS 20.0 statistical software.Result:1.The clinical efficacy: the total effective rate of the experimental group was 85%;the total effective rate of the control group was 73%,P=0.003(<0.05),indicating that the clinical efficacy of the two groups was statistically significant,and the curative effectof the test group was better than that of the control group.2.There was no statistical difference between the two groups(P > 0.05),and the experimental group was superior to the control group in reducing total bilirubin TBILs(P < 0.05).3.immunological index: both the test group and the control group could adjust the immunoglobulin(P < 0.05),and the effect of the test group was better than that of the control group(P < 0.05).4.The rapeutic effect of TCM syndromes: the total effective rate of the experimental group was 88%,and the total effective rate of the control group was 76%,P=0.019(<0.05),which indicated that the difference of the clinical curative effect between the two groups according to TCM syndromes was statistically significant,and the curative effect of the experimental group was better than that of the control group.5.Adverse reactions: no adverse reactions occurred in all cases in the trial group and the control group during the study period.Conclusion:1.Qinggan Erxian decoction can reduce the level of TBIL?IgG in type I autoimmune hepatitis with liver and kidney yin deficiency syndrome,improve the symptoms of traditional Chinese medicine,and the curative effect is better than compound glycyrrhizin tablets.2.Qinggan Erxian decoction can reduce the level of ALT?AST?ALP?GGT in type I autoimmune hepatitis with liver and kidney yin deficiency syndrome,but the curative effect is not significantly different from compound glycyrrhizin tablets.3.In the course of treating AIH with Qinggan Erxian decoction,there were no adverse reactions in the test group,which indicated that Qinggan Erxian decoction was safe and worthy of further study.